Grünenthal is Recognized for its Strong Management of Environmental, Social and Governance (ESG) Risks
- Leading global ESG ratings agency Sustainalytics notes Grünenthal is in the top five percent among its peers in the pharmaceutical subindustry
- Grünenthal is categorized as “medium risk”, placing it ahead of its key subindustry peers and in the same league as multinational companies like Pfizer and Roche
Aachen, Germany, 7 April 2021 – Grünenthal, a global science-based pharmaceutical company, today announced that Sustainalytics, a Morningstar company and a globally-recognized provider of ESG research, ratings and data, has assessed it as having overall medium ESG risk. In addition, Sustainalytics acknowledged that Grünenthal has a strong management of its ESG risks. This places Grünenthal in the top five percent of the global pharmaceuticals subsector.
“The long-term success of companies can no longer be measured by financial success alone. As a science-based company, Grünenthal strives to make a net-positive impact on the society,” said Gabriel Baertschi, CEO Grünenthal. “While we are proud to see our efforts recognized in this ESG rating, we know that a big part of the journey is still ahead of us. Building on our foundation as a responsible business, we will now integrate sustainability even more closely in our core strategy.”
Grünenthal was evaluated by Sustainalytics based on its ESG Risk Ratings framework, which focuses on exposure and management of a company’s material ESG issues. “Exposure” reflects the degree to which a company’s enterprise value is exposed to material ESG issues including ethical marketing, clinical trial transparency, whistleblowing, corruption and bribery. “Management” measures a company’s preparedness and track record in managing its exposure to material ESG issues through its policies, programmes, trainings and management systems.
The company’s ESG Risk Rating is available on Sustainalytics’ website.All data mentioned is as of 6 April 2021 and refer to the Grünenthal Pharma GmbH & Co. KG.
Grünenthal has been focusing its Environmental, Social & Governance (ESG) efforts on four pillars: educate about pain treatment and responsible use of opioids; ensure access to medicines, innovate pain management, and raise awareness for “pain as a disease”:
Educate about pain treatment and responsible use of opioids
Grünenthal has so far reached around 65,000 health care professionals in its efforts to educate the healthcare sector about pain management and improve the patient outcomes from pain treatment. As a leader in pain innovation and as an opioid manufacturer, Grünenthal is highly committed to ensuring that its employees, customers, patients and also its partners have a thorough understanding of the company’s stance on the responsible medical use of opioids in pain. The company has fostered a mindset shift along the full value chain by ensuring that all opioid-related materials contain Grünenthal’s statement on responsible use of opioids – clearly highlighting the risks and benefits of this class of medicines. In addition, Grünenthal had established a dedicated standing governance body to provide and promote clear guidance, coherent behavior, continuous improvement, training and control mechanisms.
Ensure access to medicine
Grünenthal is committed to ensuring the availability of key medicines to address unmet medical needs in the markets we serve. In the US, for instance, 5 million patients are in need of neuropathic pain treatment associated with diabetes. With the US FDA label extension of one of our non-opioid pain medicines for the treatment of neuropathic pain associated with diabetic peripheral neuropathy of the feet, Grünenthal has ensured patients get access to this much needed treatment. At the same time, the company is focused on addressing unmet therapeutic needs in underserved markets by offering specialized non-opioid pain medicines.
Innovate pain management
Grünenthal’s research and development strategy focuses on tackling in pain and collaborating with partners to address the huge unmet needs in pain. Through biennial grants of €200,000 provided by Grünenthal and the EFIC, the company supports young scientists early in their career in carrying out innovative clinical pain research. Since foundation of the EFIC-Grünenthal Grant in 2004, approximately €1.6 million was awarded to fund 65 projects. In addition, to drive patient-centric innovation in chronic pain and neurological disorders and award patient-centric and scientifically robust innovation, the company supports the Brain, Mind, and Pain Patient-Centered Innovation Grant, which awards €90,000 biennially to research proposals to encourage patient-centered innovation that leads to improvements in the life conditions of pain patients.
Raise awareness for “pain as a disease”
Chronic pain is an enormous global health problem affecting around 10% of the world’s population. Grünenthal raises awareness about the impact of pain by supporting a multi-stakeholder platform, called the Societal Impact of Pain platform, which fosters the development of pain policies on national level. With Grünenthal’s Pain Toolkit, the company has established a practical tool that provides patients with handy tips and skills in the form of explanations, infographics and videos, on how to self-manage pain. Moreover, Grünenthal has a long-standing passion for preserving the dignity and quality of life at the end stage of people’s lives. The Grünenthal Foundation for Palliative Care promotes science and research in palliative care and the care for seriously or terminally ill people in Europe as well as in Latin America.
Besides these four focus pillars, Grünenthal is covering the entire range of the Environmental, Social and Governance spectrum with various initiatives and measures:
Our efforts to promote sustainable development include defining concrete goals for the operations of our five production sites, across our supply chain and all of our affiliates across the globe by following leading international standards for environment, health and safety. We collect and analyze data from our production sites and use it to continuously improve efficiency, while also reducing energy consumption and minimizing waste based on strategic approach of zero waste to landfill programme.
Caring for its employees and for the communities where we operate is key to Grünenthal’s business conduct. Grünenthal offer its employees an exciting working environment and wide-ranging individual development opportunities. It is the company’s goal to maintain high levels of engagement and to strengthen the company as a Great Place to Work®. Grünenthal promotes a vibrant, high-performance culture and brings it to live through a shared set of values. These are supported by specific behaviours that guide the decision-making. Grünenthal ensures outstanding results are recognised and rewarded. For example, the company celebrates exceptional contributions each year with its Grünenthal Global Excellence Award.
Sound governance is key to safeguard the company’s license to operate and continue providing medicines to patients in need. Grünenthal has a comprehensive compliance and ethics management system which provides a clear framework for our decisions and actions. Grünenthal’s Code of Conduct for employees reiterates the company’s strong commitment to the highest ethical standards while the Code of Conduct for Business Partners ensures business relationships based on a reciprocal commitment to responsible behavior. Grünenthal has an external Ethics Helpline for 24/7 anonymous reporting in place to ensure compliance with the Code of Conduct. Grünenthal is also committed to full disclosure of transfers of value to healthcare professionals, healthcare organizations and patient organizations.
Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focussing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 29 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2020, Grünenthal employed around 4,500 people and achieved sales of € 1.3 bn.
More information: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
Florian Dieckmann, Head Global Communications, +49 241 569 2555, Florian.email@example.com
Fabia Kehren, Head External Communications & Editorial Management,
+49 241 569-3269
Grünenthal GmbH, 52099 Aachen, Germany
Information om Grünenthal Group
Følg pressemeddelelser fra Grünenthal Group
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Grünenthal Group
First patient enrolled into a Phase III study with QUTENZA® in post-surgical neuropathic pain10.8.2021 09:00:00 CEST | Pressemeddelelse
The study AV001 aims to include the treatment of post-surgical neuropathic pain (PSNP) in the U.S. label. QUTENZA® is currently approved for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Post-surgical neuropathic pain is a debilitating complication of surgery that affects approximately 13% of all patients who undergo surgery, representing 3.3 million patients per year in the US. Aachen, Germany, & Morristown, N.J., 10 August 2021 –Grünenthal announced today that its U.S. subsidiary, Averitas Pharma Inc., enrolled the first patient in the randomised, double-blind trial AV001. The Phase III study investigates the efficacy, safety, and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) to support an extension of the U.S. label. The trial will include over 400 patients who suffer from moderate to seve
Grünenthal’s Glucocorticoid Receptor Modulator enters clinical development27.7.2021 10:59:55 CEST | Press release
Aachen, Germany, 27 July 2021 –Grünenthal announced today that the first volunteers have been enrolled in a Phase I trial of its Glucocorticoid Receptor Modulator (GRM). The oral investigational medicine aims to provide a therapy option with broad anti-inflammatory efficacy and a more favourable benefit-risk profile compared to current glucocorticoid-based therapies like prednisolone. The Phase I trial includes 80 healthy volunteers and is designed as a head to head comparison between the GRM and prednisolone, the most frequently used glucocorticoid. Observing several biomarkers, the trial will assess the influence of the investigational medicine on bone metabolism and glucose levels. Reduced bone formation leading to osteoporosis as well as increased blood glucose levels leading to an increased risk of diabetes are among the most common side-effects of glucocorticoids, which are a strong limitation for their long-term use at highly effective doses.,, The results of the stu
Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee12.4.2021 11:14:51 CEST | Pressemeddelelse
With the acquisition of Mestex AG, Grünenthal secures global rights for an attractive late-stage asset that could offer an innovative therapy option for millions of patients affected by pain related to osteoarthritis of the knee. MTX-071 (resiniferatoxin) is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist. Its administration can reversibly defunctionalise TRPV1-expressing nociceptors. This can result in long lasting pain relief. Aachen, Germany, 12 April 2021 –Today, Grünenthal has announced the acquisition of Mestex AG through the takeover of all of its shares and options. Mestex AG is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee. The investigational medicine is currently concluding Phase II of clinical development and is about to enter Phase III. Initial data showed a long-lasting and significant analgesic effect
Grünenthal and Averitas Pharma announce initiation of Phase III study with QUTENZA® to prepare label extension in the US for the treatment of post-surgical neuropathic pain30.3.2021 15:06:52 CEST | Pressemeddelelse
Post-surgical neuropathic pain (PSNP) is a debilitating complication of surgery that affects approximately 13 percent of all patients who undergo surgery, which represents 3.3 million patients per year in the US. This Phase III study is Grünenthal’s next step in making QUTENZA available to even more patients in the United States. QUTENZA is the first and only prescription strength capsaicin that is a topical, non-systemic, non-opioid pain treatment; it is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia, and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Aachen, Germany, & Morristown, N.J., 30 March 2021 –Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc. will conduct a Phase III trial to study the efficacy, safety and tolerability of QUTENZA (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) with the goal to expand t
Grünenthal successfully extends its term loan bank facilities12.2.2021 13:34:34 CET | Pressemeddelelse
Aachen, Germany, 12 February2021–Grünenthal has announced the successful extension of its existing €535 million term loan bank facilities. This amendment was conducted in the broader context of the company’s acquisition of the European rights (excluding Spain and the UK) to the lipid-lowering medication CRESTOR™ completed in February 2021. The term loan maturities are now aligned with Grünenthal’s Revolving Credit Facility maturity, which further extends its debt maturity profile. More than 60 percent of Grünenthal’s debt facilities now mature in 2024 or later. “By extending the maturity of our financing, we have gained additional flexibility to further fund our growth strategy,” says Fabian Raschke, Chief Financial Officer of Grünenthal. „We will continue to explore opportunities to further support our organic growth with targeted acquisitions, that fit our EBITDA and cash flows accretive acquisition strategy.“ Grünenthal’s capital structure has enabled it to enter into a series of ac
Peripheral NOP agonist addressing chronic peripheral neuropathic pain enters clinical development16.12.2020 11:36:24 CET | Press release
Aachen, Germany, 16 December 2020 –Grünenthal announced today that the first participants have been enrolled in a Phase I trial of a peripherally restricted Nociceptin/orphanin peptide receptor (NOP) agonist, an oral investigational medicine with a unique mechanism of action for the treatment of chronic peripheral neuropathic pain. The Phase I trial will include 76 healthy participants. The trial aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound following single and multiple-ascending doses. The results of the study are expected to be available in 2021. “Pain remains a high unmet medical need that we strive to address with innovative medicines. Progressing our peripheral NOP agonist into clinical development is a major success in our efforts to build an industry-leading pipeline of investigational medicines,” says Jan Adams, M.D., Chief Scientific Officer, Grünenthal. “By driving the development of innova